Comparing the current results to its competitors, Xenetic Biosciences Inc reported Revenue increase in the 1 quarter 2026 by 36.01 % year on year. The sales growth was above Xenetic Biosciences Inc 's competitors' average revenue growth of 6.62 %, achieved in the same quarter.
Xenetic Biosciences Inc , slower than the average decrease reported by the company's competitors of -58.37 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -58.37 %
Xenetic Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapidly advancing technologies and a focus on proprietary products. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may lead to increased resource concentration among fewer competitors.
Strong sales growth of 36.01 % in Overall company contributed to Xenetic Biosciences Inc increase in total revenue by 36.01 % Xenetic Biosciences Inc improved its market share in this segment, to approximately 0 %.
Akari Therapeutics Plc is a biopharmaceutical company that develops and commercializes treatments for autoimmune and inflammatory diseases. Their business model revolves around conducting research, clinical trials, and obtaining regulatory approvals for their product candidates. They aim to provide innovative therapies to patients and generate revenue through the sale and licensing of their products.
Emergent Biosolutions Inc's business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Structure Therapeutics Inc is a biotechnology company that utilizes a structure-based approach to develop innovative therapeutics. They focus on identifying and targeting unique protein structures to create novel drugs for various diseases.
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
Sources:
Xenetic Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xenetic Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
